HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chris X Lu Selected Research

Therapeutics

1/2022An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chris X Lu Research Topics

Disease

3Neoplasms (Cancer)
01/2022 - 10/2012
3Breast Neoplasms (Breast Cancer)
03/2014 - 06/2012
2Neoplasm Metastasis (Metastasis)
03/2014 - 09/2013
1Disease Progression
01/2022
1Ovarian Neoplasms (Ovarian Cancer)
01/2022
1Prostatic Neoplasms (Prostate Cancer)
01/2021

Drug/Important Bio-Agent (IBA)

3Phosphotransferases (Kinase)IBA
09/2013 - 06/2012
2EnzymesIBA
01/2022 - 12/2012
2Proteins (Proteins, Gene)FDA Link
01/2022 - 10/2012
1PlatinumIBA
01/2022
1Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2022
1Poly (ADP-Ribose) Polymerase-1IBA
01/2022
1olaparibIBA
01/2022
1Cell-Free Nucleic AcidsIBA
01/2021
1Circulating Tumor DNAIBA
01/2021
1Member 1 Group A Nuclear Receptor Subfamily 4IBA
03/2014
1Indicators and Reagents (Reagents)IBA
03/2014
1CytokinesIBA
03/2014
1TNF Receptor-Associated Factor 4IBA
09/2013
1Methionine (L-Methionine)FDA Link
12/2012
1tyrosine receptor (receptor, tyrosine)IBA
10/2012
1LigandsIBA
10/2012
1Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
06/2012

Therapy/Procedure

1Therapeutics
01/2022